SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

ImageneBio, Inc. (IMA) News

Follow ImageneBio, Inc. (IMA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol IMA Asset equity Sector Markets 90 days 9 Last 3.5 Updated Nov 09, 2026, 09:25 PM UTC Open live news feed Open IMA chart & news
M ImageneBio Reports Q3 2026 Net Loss of $15.6 Million ImageneBio reported a $15.6 million net loss for the third quarter of 2026, versus $24.8 million a year earlier. It ended September with $126.6 million in cash, cash equivalents and marketable securities, which it expect EQUITY | Nov 09, 2026, 09:25 PM UTC M ImageneBio Q3 Net Loss Narrows as Expenses Fall EQUITY | Nov 09, 2026, 09:25 PM UTC L Image Resources Secures A$5 Million Cash Advance From LB Group Image Resources NL ASX:IMA NEWS | Sep 23, 2026, 01:45 AM UTC M ASX suspends Image Resources securities under Listing Rule 17.3 ASX suspended Image Resources securities from quotation under Listing Rule 17.3. EQUITY | Sep 16, 2026, 01:25 AM UTC L IMA: Olevaprubart advances in phase IIb with robust efficacy, safety, and funding into 2028 Olevaprubart, a next-generation OX40-targeting antibody, is in phase IIb trials for atopic dermatitis and alopecia areata, with strong early efficacy and a favorable safety profile. Top-line data is expected in Q4 next y NEWS | Sep 14, 2026, 08:48 PM UTC L IMA: Olevaprubart's phase IIb trial targets high efficacy and safety in atopic dermatitis, with key data due next year Olevaprubart, a next-generation OX40 antibody, is in phase IIb trials for atopic dermatitis and alopecia areata, aiming for superior efficacy and safety over prior OX40 programs. Top-line phase IIb data is expected in Q4 NEWS | Sep 14, 2026, 08:17 PM UTC L Image Resources Nl Requests Trading Halt Image Resources NL ASX:IMA NEWS | Sep 14, 2026, 12:09 AM UTC L ImageneBio CEO Kristin Yarema to speak at H.C. Wainwright conference ImageneBio (IMA) said CEO Kristin Yarema will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14. EQUITY | Sep 08, 2026, 08:37 PM UTC L IMA - ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York IMA - ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York EQUITY | Sep 08, 2026, 08:30 PM UTC M ImageneBio (IMA) reports Nasdaq inducement grants under Rule 5635(c)(4) ImageneBio (IMA) reports inducement grants under Nasdaq Listing Rule 5635(c)(4), per the company disclosure referenced by the alert. REGULATION | Aug 17, 2026, 08:30 PM UTC L IMA - ImageneBio Reports Second Quarter 2026 Financial Results IMA - ImageneBio Reports Second Quarter 2026 Financial Results EARNINGS | Aug 05, 2026, 12:00 PM UTC